The article reviews the current evidence and future potential of *Christensenella minuta* as a next-generation probiotic (NGP). *Christensenella minuta* is a member of the *Christensenellaceae* family, which has been increasingly recognized for its health benefits. The review highlights the bacterium's ability to tolerate oxygen, which facilitates its commercial production and storage. *Christensenella minuta* has demonstrated numerous beneficial properties, including anti-inflammatory effects, protection of the intestinal barrier, and potential benefits in managing metabolic disorders and inflammatory bowel diseases. The bacterium produces short-chain fatty acids (SCFAs) such as acetate and butyrate, which contribute to its therapeutic effects. Additionally, *C. minuta* can produce bile salt hydrolase, which may play a role in its biotherapeutic range. The review also discusses the challenges and future directions in the commercial production of *C. minuta*-based biotherapeutics, emphasizing the need for further research to optimize formulation and manufacturing processes. The authors suggest that *C. minuta* could be used to treat a wide range of health conditions, particularly those related to metabolic disorders and inflammatory bowel diseases, and propose the development of mixed biotherapeutics containing multiple microbial species to enhance treatment effects.The article reviews the current evidence and future potential of *Christensenella minuta* as a next-generation probiotic (NGP). *Christensenella minuta* is a member of the *Christensenellaceae* family, which has been increasingly recognized for its health benefits. The review highlights the bacterium's ability to tolerate oxygen, which facilitates its commercial production and storage. *Christensenella minuta* has demonstrated numerous beneficial properties, including anti-inflammatory effects, protection of the intestinal barrier, and potential benefits in managing metabolic disorders and inflammatory bowel diseases. The bacterium produces short-chain fatty acids (SCFAs) such as acetate and butyrate, which contribute to its therapeutic effects. Additionally, *C. minuta* can produce bile salt hydrolase, which may play a role in its biotherapeutic range. The review also discusses the challenges and future directions in the commercial production of *C. minuta*-based biotherapeutics, emphasizing the need for further research to optimize formulation and manufacturing processes. The authors suggest that *C. minuta* could be used to treat a wide range of health conditions, particularly those related to metabolic disorders and inflammatory bowel diseases, and propose the development of mixed biotherapeutics containing multiple microbial species to enhance treatment effects.